Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Sells $398,320.37 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CMO Pushkal Garg sold 1,561 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $398,320.37. Following the sale, the chief marketing officer now directly owns 13,537 shares in the company, valued at $3,454,236.29. The trade was a 10.34 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Pushkal Garg also recently made the following trade(s):

• On Tuesday, February 18th, Pushkal Garg sold 1,548 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $251.67, for a total transaction of $389,585.16.
• On Monday, January 27th, Pushkal Garg sold 52,592 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $285.00, for a total transaction of $14,988,720.00.
• On Thursday, December 12th, Pushkal Garg sold 1,752 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $251.00, for a total transaction of $439,752.00.
• On Tuesday, November 26th, Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36.

Alnylam Pharmaceuticals Trading Down 2.5 %

Shares of ALNY stock traded down $6.45 on Tuesday, hitting $250.00. The stock had a trading volume of 910,244 shares, compared to its average volume of 691,530. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39. The firm has a market cap of $32.25 billion, a P/E ratio of -95.42 and a beta of 0.35. The company has a current ratio of 2.75, a quick ratio of 2.69 and a debt-to-equity ratio of 31.64. The company has a fifty day moving average price of $254.04 and a two-hundred day moving average price of $263.44.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, analysts forecast that Alnylam Pharmaceuticals, Inc. will post -2.24 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on ALNY shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 11th. Chardan Capital restated a “buy” rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Raymond James boosted their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a research report on Friday, November 1st. Sanford C. Bernstein dropped their price objective on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. Finally, StockNews.com cut shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 9th. One analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $299.48.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Creative Planning boosted its stake in Alnylam Pharmaceuticals by 24.6% in the 3rd quarter. Creative Planning now owns 10,012 shares of the biopharmaceutical company’s stock worth $2,754,000 after purchasing an additional 1,978 shares during the period. Bleakley Financial Group LLC boosted its stake in Alnylam Pharmaceuticals by 24.7% in the 3rd quarter. Bleakley Financial Group LLC now owns 2,215 shares of the biopharmaceutical company’s stock worth $609,000 after purchasing an additional 439 shares during the period. Blue Trust Inc. boosted its stake in Alnylam Pharmaceuticals by 431.0% in the 3rd quarter. Blue Trust Inc. now owns 462 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 375 shares during the period. Allspring Global Investments Holdings LLC boosted its stake in Alnylam Pharmaceuticals by 62.2% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 420 shares of the biopharmaceutical company’s stock worth $116,000 after purchasing an additional 161 shares during the period. Finally, Signaturefd LLC boosted its stake in Alnylam Pharmaceuticals by 34.1% in the 3rd quarter. Signaturefd LLC now owns 1,854 shares of the biopharmaceutical company’s stock worth $510,000 after purchasing an additional 471 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.